RESEARCH TRIANGLE PARK, N.C., June 6, 2011 /PRNewswire/ -- (NASDAQ: GRFS).  Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, today announced the establishment of a new Board of Directors for its U.S. operations, including the appointment of Thomas Glanzmann as Chairman of the Board, who previously was president of another leading global plasma therapeutics business, and the reappointment of Gregory Rich as Chief Executive Officer (CEO) of Grifols U.S. operations.


Thomas Glanzmann was also appointed to direct the integration process because of his past leadership experience in the plasma industry and his history of successfully integrating other companies with plasma product portfolios.

"It is an honor to serve in this capacity and with such an experienced group of professionals," said Thomas Glanzmann.  "I look forward to bringing together the outstanding expertise of these two successful companies to create the world's leading plasma company," Mr. Glanzmann said. With the transaction now complete, Grifols will begin the process of integrating the two companies.  

Gregory Rich will continue as CEO of Grifols' expanded U.S. operations that now include manufacturing facilities and corporate offices in North Carolina.  "Our enlarged presence in the U.S. will provide tremendous opportunities for us to expand patient access to plasma therapies both domestically and around the world," stated Mr. Rich.  "As we integrate our two companies into one, our goal is to build on the exceptional customer service and quality operations that people have come to expect from both Grifols and Talecris," said Mr. Rich.  With more than thirty years of experience in the plasma industry associated with Grifols, Mr. Rich has driven Grifols' profitability in the U.S., serving as CEO of the US operations since 2003.